Inicio › Cáncer de pulmón de células no pequeñas › Luisiana
Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Luisiana
25 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Luisiana.
Ciudades en Luisiana
Texto oficial del estudio (inglés)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Christus Saint Frances Cabrini Hospital, Alexandria
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- y 11 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT04267848Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Pontchartrain Cancer Center - Covington Office, Covington
- Pontchartrain Cancer Center - Hammond Office, Hammond
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06472245Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University Medical Center New Orleans, New Orleans
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06498635A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Mary Bird Perkins Cancer Center, Baton Rouge
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- LSU Health Baton Rouge North Clinic ( Site 4003), Baton Rouge
- Our Lady of the Lake Physician Group-Medical Oncology ( Site 0080), Baton Rouge
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Pontchartrain Cancer Center, Covington
- Pontchartrain Cancer Center, Hammond
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Mary Bird Perkins Cancer Center, Baton Rouge
- Ochsner Health Ochsner Cancer Center - Baton Rouge, Baton Rouge
- Ochsner Clinic Foundation, New Orleans
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598Pan-tumor MRD Study
- Pontchartrain Cancer Center, Covington
- Christus Health Highlands, Shreveport
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06605404A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Louisiana State University Health Sciences Shreveport, Shreveport
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06875310Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- Our Lady of the Lake Physician's Group, Baton Rouge
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT06745882A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Mary Bird Perkins Cancer Center, Baton Rouge
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07629960A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Baton Rouge
- Research Site, Shreveport
- Research Site, Shreveport
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Covington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06767514Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-994-A, Covington
- Pontchartrain Cancer Center - Covington Office, Covington
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT04613596ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Tulane Cancer Center, New Orleans
- Christus Highland/ Boniol, Shreveport
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT05059444A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Mary Bird Perkins Cancer Center, Baton Rouge
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- LSU Health Sciences Center School of Medicine, New Orleans
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07361562A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Local Institution - 2116, New Orleans
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 27 may 2026 · NCT03093116Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Tulane Cancer Center, New Orleans
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 may 2026 · NCT07154706A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Ochsner Health, Jefferson
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 may 2026 · NCT07094204Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Mary Bird Perkins Cancer Center, Baton Rouge
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 may 2026 · NCT05379985Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Ochsner LSU Health Monroe Medical Center, Monroe
- LSU Health Sciences Center at Shreveport, Shreveport
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 mar 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Orleans
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- Ochsner/MD Anderson Cancer Center, New Orleans
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 oct 2025 · NCT06228326Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
- Our Lady of the Lake Regional Medical Center, Baton Rouge
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 18 a 100 · Mujeres · Actualizado el 20 mar 2025 · NCT06659458De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.